目的 探討芪藶強(qiáng)心膠囊聯(lián)合硫酸氫氯吡格雷片治療急性心肌梗死的臨床療效。方法 選取2022年3月—2024年7月在開封市中心醫(yī)院就診的102例急性心肌梗死患者，按隨機(jī)數(shù)字表法將患者分為對(duì)照組和治療組，每組各51例患者。對(duì)照組口服硫酸氫氯吡格雷片，2片/次，1次/d。治療組在對(duì)照組基礎(chǔ)上口服芪藶強(qiáng)心膠囊，4粒/次，3次/d。兩組均治療1個(gè)月。比較兩組的治療效果、心功能指標(biāo)、運(yùn)動(dòng)耐力和血清指標(biāo)。結(jié)果 對(duì)照組的總有效率為84.31%，治療組的總有效率為96.08%，組間比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療后，兩組的左室射血分?jǐn)?shù)（EF）、心臟指數(shù)（CI）升高，左室舒張末期容積（EDV）降低（P＜0.05）；治療組的EF、CI高于對(duì)照組，EDV低于對(duì)照組（P＜0.05）。治療后，兩組的6 min步行距離試驗(yàn)（6WMT）均升高（P＜0.05），且治療組的6WMT高于對(duì)照組（P＜0.05）。治療后，兩組的血清肌酸激酶同工酶（CK-MB）、N末端鈉尿肽前體（NT-proBNP）、同型半胱氨酸（HCY）、白細(xì)胞介素-6（IL-6）水平顯著降低（P＜0.05）；治療組的血清CK-MB、NT-proBNP、HCY、IL-6水平低于對(duì)照組（P＜0.05）。結(jié)論 芪藶強(qiáng)心膠囊聯(lián)合硫酸氫氯吡格雷片可提高急性心肌梗死的療效，進(jìn)一步改善患者心功能，降低心肌的炎性損傷。

Objective To explore the clinical efficacy of Qili Qiangxin Capsules combined with Clopidogrel Bisulfate Tablets in treatment of acute myocardial infarction. Methods 102 Patients with acute myocardial infarction who visited Kaifeng Central Hospital from March 2022 to July 2024 were selected and divided into control group and treatment group using a random number table method, with 51 cases in each group. Patients in the control group took Clopidogrel Bisulfate Tablets orally, 2 tablets/time, once daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 capsules/time, 3 times daily. Both groups were treated for one month. The therapeutic effects, cardiac function indicators, exercise endurance, and serum indicators were compared between two groups. Results The total effective rates of the control group and the treatment group were 84.31% and 96.08%, with statistical significance (P < 0.05). After treatment, EF and CI in two groups were increased, while EDV was decreased (P < 0.05). EF and CI of the treatment group were higher than those of the control group, but EDV was lower than that of the control group (P < 0.05). After treatment, 6WMT distance of two groups were increased (P < 0.05), and 6WMT distance of the treatment group was higher than that of the control group (P < 0.05). After treatment, the serum levels of CK-MB, NT-proBNP, HCY, and IL-6 in two groups were significantly decreased (P < 0.05), and those in the treatment group were lower than those in the control group (P < 0.05). Conclusion Qili Qiangxin Capsules combined with Clopidogrel Bisulfate Tablets can improve the therapeutic effect of acute myocardial infarction, further improve patients' cardiac function, and reduce myocardial inflammatory damage.

R972

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目（LHGJ20220927）